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To the Editor:
We read with interest the excellent review of Al-Malki
et al. on hematopoietic stem cell transplantation (HSCT)
for plasmablastic lymphoma (PBL) [1]. The authors con-
clude that autologous HSCT (autoHSCT) might be beneﬁ-
cial both in the salvage setting and for consolidation
of ﬁrst-line responses in this orphan lymphoma subset,
which has a very poor prognosis with conventional
chemotherapy [2]. As this suggestion is largely based
on anecdotal data, we would like to substantiate the
evidence supporting autoHSCT in PBL by reporting the
European Society for Blood and Marrow Transplantation
experience.
Between 2001 and 2011, data pertaining to 24 patients,
who underwent autoHSCT for PBL and had a full MED-A
(minimal essential dataset A) available were reported
to the European Society for Blood and Marrow Trans-
plantation registry. The patient population showed a male
predominance (75%) and a relatively young age (median,
43 years; range, 16 to 63), typical for PBL [2]. The majority
of transplantations were performed in ﬁrst complete
(50%) or partial (17%) remission, and in 71% of the
patients BEAM (carmustine, etoposide, ara-C, melphalan)
or modiﬁcations of BEAM were used as a myeloablative
regimen. Human immune deﬁciency virus (HIV) status
was available for only 8 patients and was positive in 7
of them.
Of the 24 patients, 7 relapsed after autoHSCT, translating
into a 2-year relapse rate of 30% (95% conﬁdence interval [CI],
8% to 57%). In these 7 patients, disease status at HSCT was
ﬁrst complete remission (CR) in 2, ﬁrst partial remission in 2,
third partial remission in 1, and refractory disease in 2 pa-
tients. Notably, no relapse was observed beyond 4 months
from transplantation. Except a single patient who was lost to
follow-up, all relapsed patients subsequently died, most of
them within a short time period after disease recurrence. In
addition, there were 3 nonrelapse deaths (1 from sepsis, 1
from progressive HIV infection, and 1 from a secondary T cell
lymphoma), translating into a 2-year overall survival prob-
ability of 53% (95% CI, 28% to 73%). Patients who were auto-
grafted in CR had a signiﬁcantly lower relapse risk (hazard
ratio, 11.7; 95% CI, 1.98 to 68.9) and overall mortality risk
(hazard ratio, 15.6; 95% CI, 2.62 to 92.5) than more advanced
patients. In contrast, neither age, gender, interval from
diagnosis to autoHSCT, performance status, high-dose
regimen, nor calendar year of transplantation had a signiﬁ-
cant impact on survival.
Limitations of this analysis consist in its retrospective
character, the small sample size, a paucity of information
about pretransplantation treatment, and the median follow-
up of survivors, which was only 30 months (range, 3
to 132; interquartile range, 3 to 63). However, as there
were 11 patients who remained relapse free and survived
6 months or longer, our series supports the notion that
autoHSCT might have the potential to induce sustained
remissions in PBL given the extremely short interval to
disease recurrence in all patients who experienced post-
transplantation relapse. This implies that there is a ratio-
nale to consider autoHSCT as soon as a ﬁrst CR is
achieved. In conclusion, in the absence of effective treat-
ment alternatives, autoHSCT deserves to be further explored
as consolidation for ﬁrst-line and salvage therapy of PBL
both in the HIVþ and HIV setting [3].
Financial disclosure: See Acknowledgments on page 1147.
* Correspondence and reprint requests: Dr. Peter Dreger, Department of
Medicine V, University of Heidelberg, Im Neuenheimer Feld 410, 69120
Heidelberg, Germany.
E-mail address: peter.dreger@med.uni-heidelberg.de (P. Dreger).
1083-8791/ 2015 American Society for Blood andMarrow Transplantation.
http://dx.doi.org/10.1016/j.bbmt.2015.03.008
Letters to the Editor / Biol Blood Marrow Transplant 21 (2015) 1145e11471146
ACKNOWLEDGMENTS
We thank all European Society for Blood and
Marrow Transplantation centers that participated in this
study.
Financial disclosure: The authors have nothing to
disclose.
Conﬂict of interest statement: The authors have no conﬂict
of interest to declare.
REFERENCES
1. Al-Malki MM, Castillo JJ, Sloan JM, Re A. Hematopoietic cell trans-
plantation for plasmablastic lymphoma: a review. Biol Blood Marrow
Transplant. 2014;20:1877-1884.
2. Stein H, Harris N, Campo E. Plasmablastic lymphoma. In: Swerdlow S,
Campo E, Harris N, et al., editors. WHO Classiﬁcation of Tumors of the He-
matopoietic andLymphoidTissues, 4thed. Lyon, France: IARC;2008.p.256-257.
3. Balsalobre P, Diez-Martin JL, Re A, et al. Autologous stem-cell trans-
plantation in patients with HIV-related lymphoma. J Clin Oncol. 2009;27:
2192-2198.
Letters to the Editor / Biol Blood Marrow Transplant 21 (2015) 1145e1147 1147
